arteflene has been researched along with Melanoma* in 1 studies
1 other study(ies) available for arteflene and Melanoma
Article | Year |
---|---|
The antimalarial drug, Ro 42-1611 (arteflene), does not affect cytoadherence and cytokine-inducing properties of Plasmodium falciparum malaria parasites.
The purpose of this study was to investigate the ability of the antimalarial drug, Ro 42-1611 to block parasite mediated cytokine induction in vitro as well as cytoadherence of infected erythrocytes to melanoma cells in vitro. The biological activity of Ro 42-1611 was confirmed as it blocked Plasmodium falciparum growth in cultures. Ro 42-1611, had no major effect on TNF, IL-alpha or IL-6 cytokine release from mononuclear cells stimulated with malaria antigens or lipopolysaccharide and it did not affect cell viability. Ro 42-1611 only slightly suppressed cytoadherence of infected erythrocytes to melanoma cells. The therapeutic effect of To 42-1611 appears to be confined to its parasite killing activity. Topics: Adult; Animals; Antigens, Protozoan; Antimalarials; Artemisinins; Bridged Bicyclo Compounds, Heterocyclic; Cell Adhesion; Cell Survival; Chloroquine; Cytokines; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Erythrocytes; Humans; Immunoglobulin G; Interleukin-1; Interleukin-6; Lipopolysaccharides; Lymphocytes; Malaria, Falciparum; Mefloquine; Melanoma; Plasmodium falciparum; Styrenes; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1995 |